Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.
Study Type
OBSERVATIONAL
Enrollment
100
University of Regensburg
Regensburg, Germany
RECRUITINGChange of IP10 and related cytokines during treatment (ng/ml)
Screening for Biomarkers under DAA Therapy until timepoint SVR 12 (12 weeks treatment plus control 12 weeks after end of Treatment = 24 weeks)
Time frame: 24 weeks (observation time under and after DAA therapy)
SVR 12
Eradication of HCV RNA 12 weeks after end of Treatment (Treatment 12 weeks)
Time frame: 24 weeks (12 weeks treatment plus control 12 weeks after end of treatment)
Change of inflammatory markers (ferritin ng/ml, CRP mg/l, PCT ng/ml) during treatment
Time frame: 24 weeks (observation time under DAA therapy)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.